Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Non-Current Deffered Revenue (2016 - 2026)

Iradimed has reported Non-Current Deffered Revenue over the past 14 years, most recently at $3.8 million for Q1 2026.

  • Quarterly Non-Current Deffered Revenue rose 17.35% to $3.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Mar 2026, up 17.35% year-over-year, with the annual reading at $4.0 million for FY2025, 32.91% up from the prior year.
  • Non-Current Deffered Revenue was $3.8 million for Q1 2026 at Iradimed, down from $4.0 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $4.0 million in Q4 2025 and troughed at $1.4 million in Q4 2022.
  • The 5-year median for Non-Current Deffered Revenue is $2.8 million (2024), against an average of $2.8 million.
  • Year-over-year, Non-Current Deffered Revenue fell 29.82% in 2022 and then surged 103.14% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $1.4 million in 2022, then surged by 103.14% to $2.8 million in 2023, then increased by 7.14% to $3.0 million in 2024, then surged by 32.91% to $4.0 million in 2025, then fell by 5.56% to $3.8 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Non-Current Deffered Revenue are $3.8 million (Q1 2026), $4.0 million (Q4 2025), and $3.6 million (Q3 2025).